Castrate-Resistant Prostate Cancer Market Size is Expected to Grow by 2032 | DelveInsight

Castrate-Resistant Prostate Cancer Market Size is Expected to Grow by 2032 | DelveInsight

DelveInsight’s “Castrate-resistant Prostate Cancer (CRPC) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Castrate-resistant Prostate Cancer (CRPC), historical and forecasted epidemiology as well as the Castrate-resistant Prostate Cancer (CRPC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Key Takeaways from the Castrate resistant Prostate Cancer Market Research Report

  • The increase in Castrate resistant Prostate Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Castrate resistant Prostate Cancer market is anticipated to witness growth at a considerable CAGR.
  • The leading Castrate resistant Prostate Cancer Companies working in the market include Bayer HealthCare, along with Astellas Pharma, Janssen Pharmaceutical, Sanofi, Bayer HealthCare in collaboration with Orion Corporation, AstraZeneca in partnership with Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Hinova Pharmaceuticals, Innocrin Pharmaceutical, Orion Pharma, Immunomedics, Merck Sharp & Dohme, Hoffmann-La Roche, Pfizer in alliance with Astellas Pharma, AstraZeneca, BeiGene, Clovis Oncology, Janssen Research & Development, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and others.
  • Promising Castrate resistant Prostate Cancer Pipeline Therapies in the various stages of development include AZD4635, Durvalumab, Cabazitaxel, tomivosertib (eFT508), Atezolizumab, Radium-223 Dichloridem, and others.
  • April 2024: AbbVie announced a study of Phase 1 clinical trials for ABBV-969. Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy.
  • April 2024: Astellas Pharma Europe Ltd. announced a study of  Phase 3 clinical trials for Enzalutamide, Docetaxel and Prednisolone. The purpose of the study was to understand if there was benefit in continued treatment with a medicine called enzalutamide, when starting treatment with docetaxel and prednisolone (a standard chemotherapy for prostate cancer), after the prostate cancer had gotten worse when treated with enzalutamide alone.
  • April 2024: Bayer announced a study of Phase 1 clinical trials for BAY3546828, BAY2616505 and BAY2315493. The study will have two parts. The first part, called dose escalation, is done to find the most appropriate dose and schedule that can be given in the second part of the study. For this, each participant will receive one of the predefined increasing doses of 225Ac-pelgi as an infusion into the vein. All participants in part 2, called dose expansion, will receive the most appropriate dose and schedule identified from the first part of the study. More than one dose level or schedule from part 1 may be tested. Both the participants and the study team know what treatment the participants will take.

 

Discover which therapies are expected to grab the Castrate resistant Prostate Cancer Market Share @ Castrate resistant Prostate Cancer Market Outlook

 

Castrate resistant Prostate Cancer Overview

Castration-resistant prostate cancer (CRPC) is a form of prostate cancer that no longer responds to hormone therapy, also known as androgen deprivation therapy (ADT). ADT works by reducing the levels of male hormones, particularly testosterone, in the body, as these hormones can fuel the growth of prostate cancer cells.

 

Castrate resistant Prostate Cancer Epidemiology Insights

 The epidemiology section of Castrate resistant Prostate Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

 

Download the report to understand which factors are driving Castrate resistant Prostate Cancer Epidemiology trends @ Castrate resistant Prostate Cancer Epidemiological Insights

 

Castrate resistant Prostate Cancer Drugs Market

The Castrate resistant Prostate Cancer Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Castrate resistant Prostate Cancer signaling in Castrate resistant Prostate Cancer are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Castrate resistant Prostate Cancer Treatment Market Landscape

The Castrate resistant Prostate Cancer treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Castrate resistant Prostate Cancer has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Castrate resistant Prostate Cancer treatment guidelines, visit @ Castrate resistant Prostate Cancer Treatment Market Landscape

 

Castrate resistant Prostate Cancer Market Outlook

The report’s outlook on the Castrate resistant Prostate Cancer market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Castrate resistant Prostate Cancer therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Castrate resistant Prostate Cancer drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Castrate resistant Prostate Cancer market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Castrate resistant Prostate Cancer Drugs Uptake

The drug chapter of the Castrate resistant Prostate Cancer report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, disadvantages of each drug, as well as the latest news and press releases related to Castrate resistant Prostate Cancer.

 

Major Castrate resistant Prostate Cancer Companies

Several companies working in the market include Bayer HealthCare, Astellas Pharma, Janssen Pharmaceutical, Sanofi, Bayer HealthCare in collaboration with Orion Corporation, AstraZeneca in partnership with Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Hinova Pharmaceuticals, Innocrin Pharmaceutical, Orion Pharma, Immunomedics, Merck Sharp & Dohme, Hoffmann-La Roche, Pfizer in alliance with Astellas Pharma, AstraZeneca, BeiGene, Clovis Oncology, Janssen Research & Development, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and others.

 

Learn more about the FDA-approved drugs for Castrate resistant Prostate Cancer @ Drugs for Castrate resistant Prostate Cancer Treatment

 

Scope of the Castrate resistant Prostate Cancer Market Research Report

  • Coverage- 7MM
  • Study Period- 20190-2032
  • Castrate resistant Prostate Cancer Companies- Bayer HealthCare, along with Astellas Pharma, Janssen Pharmaceutical, Sanofi, Bayer HealthCare in collaboration with Orion Corporation, AstraZeneca in partnership with Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Hinova Pharmaceuticals, Innocrin Pharmaceutical, Orion Pharma, Immunomedics, Merck Sharp & Dohme, Hoffmann-La Roche, Pfizer in alliance with Astellas Pharma, AstraZeneca, BeiGene, Clovis Oncology, Janssen Research & Development, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and others.
  • Castrate resistant Prostate Cancer Pipeline Therapies- AZD4635, Durvalumab, Cabazitaxel, tomivosertib (eFT508), Atezolizumab, Radium-223 Dichloridem, and others.
  • Castrate resistant Prostate Cancer Market Dynamics: Castrate resistant Prostate Cancer Market Drivers and Barriers
  • Castrate resistant Prostate Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Castrate resistant Prostate Cancer Drugs in development @ Castrate resistant Prostate Cancer Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of Castrate-resistant Prostate Cancer (CRPC)

3. Competitive Intelligence Analysis for Castrate-resistant Prostate Cancer (CRPC)

4. Castrate-resistant Prostate Cancer (CRPC): Market Overview at a Glance

5. Castrate-resistant Prostate Cancer (CRPC): Disease Background and Overview

6. Patient Journey

7. Castrate-resistant Prostate Cancer (CRPC) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Castrate-resistant Prostate Cancer (CRPC) Unmet Needs

10. Key Endpoints of Castrate-resistant Prostate Cancer (CRPC) Treatment

11. Castrate-resistant Prostate Cancer (CRPC) Marketed Products

12. Castrate-resistant Prostate Cancer (CRPC) Emerging Therapies

13. Castrate-resistant Prostate Cancer (CRPC): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Castrate resistant Prostate Cancer Market Outlook

16. Access and Reimbursement Overview of Castrate-resistant Prostate Cancer (CRPC)

17. Castrate resistant Prostate Cancer KOL Views

18. Castrate resistant Prostate Cancer Market Drivers

19. Castrate resistant Prostate Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight


Posted

in

by

Tags: